We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

216 hedge funds and large institutions have $3.86B invested in Amicus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 82 increasing their positions, 73 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $11.5M | Put options by funds: $4.95M

17% more capital invested

Capital invested by funds: $3.3B → $3.86B (+$557M)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 73

2.67% more ownership

Funds ownership: 105.31%107.98% (+2.7%)

4% less funds holding

Funds holding: 226216 (-10)

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

Holders
216
Holders Change
-10
Holders Change %
-4.42%
% of All Funds
3.39%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
25
Increased
82
Reduced
73
Closed
32
Calls
$11.5M
Puts
$4.95M
Net Calls
+$6.55M
Net Calls Change
+$8.49M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$29M +$1.21M +102,383 +5%
William Blair Investment Management
27
William Blair Investment Management
Illinois
$29M +$303K +25,573 +1%
Charles Schwab
28
Charles Schwab
California
$26.5M +$473K +39,859 +2%
NHAS
29
Novo Holdings A/S
Denmark
$26.3M
O
30
OrbiMed
New York
$23.3M +$8.13M +685,400 +59%
Massachusetts Financial Services
31
Massachusetts Financial Services
Massachusetts
$18.6M +$17.6M +1,481,286 New
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$18.4M -$461K -38,854 -3%
T. Rowe Price Associates
33
T. Rowe Price Associates
Maryland
$17.5M -$906K -76,388 -5%
PAM
34
Panagora Asset Management
Massachusetts
$16.7M -$398K -33,521 -2%
FC
35
Finepoint Capital
Massachusetts
$16.7M -$1.59M -134,400 -9%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$14.8M +$58.7K +4,944 +0.4%
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$14.2M -$6.17M -519,671 -31%
Primecap Management
38
Primecap Management
California
$13.7M -$702K -59,200 -5%
RSCM
39
Rock Springs Capital Management
Maryland
$13.4M
RHJA
40
Rice Hall James & Associates
California
$13.2M +$2.39M +201,804 +24%
VOYA Investment Management
41
VOYA Investment Management
Georgia
$11.2M +$1.88M +158,488 +22%
N
42
Nuveen
North Carolina
$10.2M +$53.1K +4,476 +0.6%
Invesco
43
Invesco
Georgia
$9.63M -$1.97M -165,651 -18%
Prudential Financial
44
Prudential Financial
New Jersey
$9.49M +$254K +21,410 +3%
Wells Fargo
45
Wells Fargo
California
$9.39M +$661K +55,739 +8%
SAM
46
Sectoral Asset Management
Quebec, Canada
$9.17M +$2.49M +209,942 +40%
PCM
47
Peregrine Capital Management
Minnesota
$8.91M -$1.03M -86,893 -11%
GPP
48
Great Point Partners
Connecticut
$8.81M +$3.81M +321,392 +85%
CS
49
Candriam SCA
Luxembourg
$8.72M
Rafferty Asset Management
50
Rafferty Asset Management
New York
$8.15M +$639K +53,811 +9%

FOLD Hedge Fund Activity: Q2 2023 in Review

216 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2023, worth a combined $3.86B — up 17% from $3.3B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of FOLD and 25 opened new positions — a net loss of 7 holders — while 73 trimmed existing stakes and 82 added.

The largest buyer was Deutsche Bank, adding an estimated $61.1M. The largest seller was Morgan Stanley, cutting an estimated $40.8M.

  • 216 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2023, down from 226 in Q1 2023.
  • Funds reported $3.86B of Amicus Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
  • 25 funds opened new Amicus Therapeutics positions in Q2 2023 and 32 closed out, a net change of -7 holders.
  • The largest Amicus Therapeutics buyer in Q2 2023 was Deutsche Bank, an estimated $61.1M added.
  • The largest Amicus Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $40.8M sold.

Based on aggregated 13F filings for Q2 2023.